LB PHARMACEUTICALS

Company snapshot

LB Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of schizophrenia. Our lead drug candidate is a second-generation antipsychotic and a potential first-in-class benzamide to enter the U.S. market. With robust clinical development underway and a focus on long-term patient outcomes, we aim to set a new standard of care for neuropsychiatric condit

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for LB PHARMACEUTICALS. Not investment advice.

• Peer + 0 momentum

  Vanda Pharmaceuticals Netherlands

  TA overlap score 32

• Peer + 0 momentum

  BioXcel Therapeutics

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for LB PHARMACEUTICALS.

1. Jun 5, 2026 Clinical update

   LB-102 (50 mg tablet) — Phase 3

2. May 23, 2026 Clinical update

   LB-102 — Phase 3

3. May 23, 2026 Clinical update

   LB-102 — Phase 2

4. Aug 13, 2024 Patent grant

   Psychotropic agents and uses thereof

5. Aug 1, 2023 Patent grant

   Psychotropic agents and uses thereof

View all clinical trial activity →

• What is LB PHARMACEUTICALS?

  LB PHARMACEUTICALS is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker LBRX. Primary therapeutic focus areas include Schizophrenia, Bipolar I Disorder. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 7 patent record(s) to thi

• Is LB PHARMACEUTICALS publicly traded?

  Yes. LB PHARMACEUTICALS is listed with ticker LBRX on NYSE per SEC EDGAR records linked on this profile.

• What drugs does LB PHARMACEUTICALS develop or market?

  We link 1 drug profile(s) where LB PHARMACEUTICALS is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/lb-pharmaceuticals-inc#company-drugs.

• What are the latest developments for LB PHARMACEUTICALS?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does LB PHARMACEUTICALS focus on?

  LB PHARMACEUTICALS focuses on Schizophrenia, Bipolar I Disorder based on our analysis of their pipeline programs and drug development activities.